Birzeit Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Birzeit Pharmaceuticals's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 7.9% per year. Birzeit Pharmaceuticals's return on equity is 5.9%, and it has net margins of 14.2%.
Key information
-0.6%
Earnings growth rate
-0.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 7.9% |
| Return on equity | 5.9% |
| Net Margin | 14.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Birzeit Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 43 | 6 | 8 | 0 |
| 30 Sep 23 | 44 | 6 | 7 | 0 |
| 30 Jun 23 | 45 | 6 | 7 | 0 |
| 31 Mar 23 | 45 | 7 | 7 | 0 |
| 31 Dec 22 | 47 | 8 | 7 | 0 |
| 30 Sep 22 | 47 | 10 | 8 | 0 |
| 30 Jun 22 | 48 | 12 | 8 | 0 |
| 31 Mar 22 | 50 | 14 | 7 | 0 |
| 31 Dec 21 | 45 | 12 | 7 | 0 |
| 30 Sep 21 | 43 | 11 | 7 | 0 |
| 30 Jun 21 | 40 | 10 | 7 | 0 |
| 31 Mar 21 | 35 | 7 | 7 | 0 |
| 31 Dec 20 | 36 | 7 | 7 | 0 |
| 30 Sep 20 | 35 | 8 | 7 | 0 |
| 30 Jun 20 | 35 | 8 | 8 | 0 |
| 31 Mar 20 | 35 | 8 | 7 | 0 |
| 31 Dec 19 | 35 | 10 | 7 | 0 |
| 30 Sep 19 | 33 | 8 | 7 | 0 |
| 30 Jun 19 | 32 | 7 | 6 | 0 |
| 31 Mar 19 | 35 | 8 | 6 | 0 |
| 31 Dec 18 | 36 | 8 | 6 | 0 |
| 30 Sep 18 | 35 | 10 | 6 | 0 |
| 30 Jun 18 | 34 | 10 | 6 | 0 |
| 31 Mar 18 | 33 | 11 | 6 | 0 |
| 31 Dec 17 | 33 | 11 | 6 | 0 |
| 30 Sep 17 | 34 | 8 | 6 | 0 |
| 30 Jun 17 | 34 | 9 | 6 | 0 |
| 31 Mar 17 | 34 | 8 | 6 | 0 |
| 31 Dec 16 | 32 | 8 | 5 | 0 |
| 30 Sep 16 | 30 | 6 | 5 | 0 |
| 30 Jun 16 | 28 | 5 | 5 | 0 |
| 31 Mar 16 | 28 | 5 | 5 | 0 |
| 31 Dec 15 | 26 | 5 | 5 | 0 |
| 30 Sep 15 | 27 | 5 | 5 | 0 |
| 30 Jun 15 | 27 | 5 | 5 | 0 |
| 31 Mar 15 | 26 | 5 | 5 | 0 |
| 31 Dec 14 | 25 | 4 | 5 | 0 |
| 30 Sep 14 | 25 | 6 | 5 | 0 |
| 30 Jun 14 | 25 | 7 | 5 | 0 |
| 31 Mar 14 | 26 | 5 | 5 | 0 |
| 31 Dec 13 | 25 | 5 | 5 | 0 |
| 30 Sep 13 | 25 | 5 | 5 | 0 |
| 30 Jun 13 | 24 | 6 | 5 | 0 |
Quality Earnings: BPC has high quality earnings.
Growing Profit Margin: BPC's current net profit margins (14.2%) are lower than last year (16.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPC's earnings have declined by 0.6% per year over the past 5 years.
Accelerating Growth: BPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BPC had negative earnings growth (-23%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.5%).
Return on Equity
High ROE: BPC's Return on Equity (5.9%) is considered low.